頁籤選單縮合
題名 | 非小細胞癌的免疫治療=Immunotherapy for Non-small Cell Lung Cancer |
---|---|
作者姓名(中文) | 施穎銘; 洪淑淓; 張純琪; | 書刊名 | 內科學誌 |
卷期 | 28:5 2017.10[民106.10] |
頁次 | 頁271-278 |
分類號 | 418.93 |
關鍵詞 | 非小細胞肺癌; 免疫治療; 免疫檢查點抑制; Non-small cell lung cancer; Immunotherapy; Immune check point blockade; |
語文 | 中文(Chinese) |
中文摘要 | 晚期非小細胞肺癌是高度致命的癌症,過去治療的選擇只有化學治療或標靶治療。免疫檢查點抑制劑是目前唯一證實有效的免疫治療,它藉由PD-1、PD-L1 或CTLA-4 負向調控T 細胞功能,增強其對腫瘤細胞的攻擊達到治療的效果。Nivolumab 和Pembrolizumab 是PD-1 單株抗體,Nivolumab 適用於晚期非小細胞肺癌病人的第二線治療,不須檢測癌細胞PD-L1;Pembrolizumab 適用在癌細胞PD-L1 陽性的晚期非小細胞肺癌病人的第一線或第二線治療。Atezolizumab 是PD-L1 的單株抗體,適用於晚期非小細胞肺癌病人的第二線治療,不須檢測癌細胞PD-L1。免疫治療後腫瘤的變化和傳統治療不同,治療的效果要用免疫相關反應評估標準追蹤。免疫檢查點抑制劑治療後產生的副作用比化療低,但少數病人會有免疫相關副作用,需要及早發現並加以處理。 |
英文摘要 | Advanced or end stage non-small cell lung cancer(NSCLC) is a highly lethal disease. Current treatment is limited to chemotherapy or targeted therapy. Immune check point blockade is the only proven effective immunotherapy in NSCLC. Antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise results against cancer cells. However, immunotherapy presents unusual kinetics of tumor response, immune-related response criteria (irRC) was developed to evaluate therapeutic benefit. Although immunotherapy has a more favorable adverse event profile compared with chemotherapy, it generates dysimmune toxicities called immune-related adverse events (irAEs). Early identification and management of irAEs can optimize outcomes. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。